Heron Therapeutics | HRTX - Actif À Court Terme





Actif À Court Terme Changement Date
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
ANI Pharmaceuticals USD 753.12M 54.72M 2025-12
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
Eisai JPY 840.88B 50.18B 2025-12
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Heron Therapeutics USD 238.07M 8.67M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
Merck USD 35.02B 8.5B 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Omeros USD 69.65M 26.53M 2025-06
Pacira USD 514.96M 33.01M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Surmodics USD 75.99M 5.31M 2025-06
Ultragenyx Pharmaceutical USD 951M 307.79M 2025-12
Veracyte USD 488.38M 39.15M 2025-12
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03